

06-2-00

06/01/00
JC821 U.S. PTO

7

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 5750-8B

JC821 U.S. PTO

06/01/00
JC821 U.S. PTO

First Inventor or Application Identifier: Halvorsen, et al.

Title of Invention: METHODS AND COMPOSITIONS FOR THE DIFFERENTIATION OF HUMAN PREADIPOCYTES INTO ADIPOCYTES

Express Mail Label No. EL247265315US

ADDRESS TO: ASSISTANT COMMISSIONER FOR PATENTS
BOX PATENT APPLICATION
WASHINGTON, DC 20231

Transmitted herewith for filing in the United States Patent Office is a patent application for:

Inventors: Yuan-Di Chang Halvorsen and William O. Wilkison

1. The Filing Fee has been calculated as shown below:

No. Filed	No. Extra	Small Entity	Large Entity		
		Rate	Fee 1	Rate	Fee 0
BASIC FEE		\$345	\$0		
TOTAL CLAIMS: 6 - 20 =	0	X 9 = \$0	x 18 = \$0		
INDEP CLAIMS: 6 - 3 =	3	X 39 = \$117	x 78 = \$0		
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED		+130 = \$	+260 = \$		
*If the difference in Column 1 is less than zero, enter "0" in Column 2.		TOTAL \$462	TOTAL \$		

The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No 16-0605.

a. Fees required under 37 CFR 1.16 (National filing fees).
 b. Fees required under 37 CFR 1.17 (National application processing fees).
 A check in the amount of \$ ___ for the filing fee is enclosed.
 The above filing fee will be paid along with Applicant(s) Response to the Notice to File Missing Parts.

2. Specification; Total Pages 30

3. 8 Sheets of Formal Drawing(s) (35 USC 113)

4. Declaration and Power of Attorney; *[Total Pages ___]*
a. Newly executed (original or copy)
b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 16 completed)
i. DELETION OF INVENTOR(S) Signed statement
attached deleting inventor(s) named in the prior
application, see 37 CFR 1.63(d)(2) & 1.33(b).

5. Microfiche Computer Program (Appendix)

6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
a. Computer Readable Copy
b. Paper Copy (identical to computer copy)
c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. Assignment Papers (cover sheet & document(s) (including a check for
the \$40.00 fee)

8. 37 CFR 3.73(b) Statement (*when there is an assignee*); Power of Attorney

9. English Translation Document (*if applicable*)

10. Information Disclosure Statement (IDS)/PTO-1449; ___ Copies of IDS Citations

11. Preliminary Amendment

12. Return Receipt Postcard (MPEP 503) (*Should be specifically itemized*)

13. Small Entity Statement(s)
 Statement filed in prior application; status still proper and desired.

14. Certified Copy of Priority Document(s) (*if foreign priority is claimed*)
Foreign Priority is

15. Other: ___

16. **If a CONTINUING APPLICATION, check appropriate box and supply the requisite
information below and in a preliminary amendment:**

Continuation Divisional Continuation in Part (CIP)
of prior Application No: 09/240,029; Filed January 29, 1999

Prior Application Information: Examiner S. Saucier Group/Art Unit: 1651

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration
is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is
hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the
submitted application parts.

17. **CORRESPONDENCE ADDRESS**

Customer Number or Bar Code Label **000826**

Attention Of: W. Murray Spruill

Signature:

Robert E. McCarthy

Attorney/Agent of Record: Robert E. McCarthy

Attorney/Agent Registration No. 46,044

Tel Raleigh Office (919) 420-2200

Fax Raleigh Office (919) 420-2260

ALSTON & BIRD LLP

P.O. Drawer 34009

Charlotte NC 28234-4009

"Express Mail" mailing label number EL247265315US

Date of Deposit June 1, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner For Patents, Washington, DC 20231.

Pamela Lockley

Pamela Lockley

RTA01/2078735v1

METHODS AND COMPOSITIONS FOR THE DIFFERENTIATION OF
HUMAN PREADIPOCYTES INTO ADIPOCYTES

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. Application Serial No. 09/240,029, filed January 29, 1999 which is herein incorporated by reference.

FIELD OF THE INVENTION

The invention is drawn to the field of adipocyte biology. Methods and compositions are provided for the differentiation of human preadipocytes into adipocytes.

5

BACKGROUND OF THE INVENTION

Non-insulin dependent diabetes mellitus (NIDDM) afflicts 4-5 million Americans every year. NIDDM is treated predominately with insulin. However, insulin is not 10 convenient to use in that it must be injected 2-4 times per day and must be stored properly to prevent loss of efficacy. Other drugs used to treat NIDDM include troglitazone (RezulinTM), a PPAR γ agonist, GlucophageTM and sulfonylureas. Unfortunately, there are safety concerns related to the use of these drugs. The identification of safe, effective, orally available drugs for the treatment of NIDDM would greatly enhance the quality of

life of patients who suffer from this disease. However, studies to find such molecules have been hampered by a lack of reproducible human *in vitro* cell systems.

Approximately 20-25% of Americans are obese and therefore at increased risk for developing NIDDM, hypertension, and cardiovascular disease. The causes of NIDDM and obesity are often related to defects or problems with adipose tissue. Adipocytes play a critical role in lipid storage and metabolism. Adipocytes also act as endocrine cells to influence physiological parameters such as insulin sensitivity and body weight (Flier, *et al.*, *Cell*, (1995) 80:15-18; the contents of which are incorporated herein by reference). For example, the *ob* gene encodes leptin, an adipocyte-secreted endocrine factor (Zhang, *et al.*, *Nature* (1994) 372:425-432). Leptin has been shown to reduce body weight and blood glucose in obese, diabetic rodents (Pelleymounter, *et al.*, *Science*, (1995) 269:540-543).

Several adipocyte-specific enzymes and receptors have been shown to be important targets for anti-obesity and anti-diabetic drug discovery. For example, agonists of the β 3 adrenergic receptor, which is found predominantly in the adipose tissue in man (Arner, *et al.*, *New England Journal of Medicine*, (1995) 333:382-383; the contents of which are incorporated herein by reference), have anti-obesity and anti-diabetic properties in rodents and are currently in phase II/III trials in man. The thiazolidinedione class of compounds (TZDs), including troglitazone and ciglitazone, has been shown to improve insulin sensitivity and thereby reduce hyperglycemia and hyperlipidemia conditions in rodents and in humans (Saltiel, *et al.*, *Diabetes*, (1996) 45:1661-1669; Sreenan, *et al.*, *American Journal Physiol*, (1996) 271:E742-E747; Nolan, *et al.*, *New England Journal of Medicine*, (1994) 331:1188-1193; the contents of which are incorporated herein by reference. Troglitazone (RezulinTM) is approved for use in the U.S. and Japan. Many TZDs, including troglitazone and ciglitazone, are potent activators of Peroxisome Proliferator Activated Receptor gamma (PPAR γ), a member of the nuclear receptor family of transcription factors (Tontonoz, *et al.*, *Cell*, (1994) 79:1147-1156; Lehmann, *et al.*, *Journal of Biological Chemistry*, (1995) 270:12953-12955; the contents of which are incorporated herein by reference). PPAR γ is a key regulator of adipocyte differentiation and is most abundant in adipose tissue.

Animal adipocyte studies have been facilitated by the availability of a number of immortalized preadipocyte cell lines such as the 3T3-L1 mouse fibroblast line (Green, *et al.*, *Cell*, (1974) 1:113-116; the contents of which are incorporated herein by reference), which upon proper treatment, will differentiate into adipocytes. These cells have many of

5 the same properties as isolated primary adipocytes. However, recent published reports show that human adipose tissue and adipocytes exhibit significant differences from rodent cells with respect to factors affecting insulin resistance. For example, TNF α appears to be regulated differently in human adipose tissue than in rodent adipose tissue (Hotamisligil, *et al.*, *Journal of Clin Invest*, (1995) 95:2409-2415; the contents of which

10 are incorporated herein by reference). Consequently, studies on human adipocytes and adipose metabolism have been hampered by the lack of a preadipocyte cell culture that can be reproducibly induced to differentiate into adipocytes at high efficiency.

Current protocols for differentiating isolated human preadipocytes result in differentiation frequencies of 5-80%. In these systems, the preadipocyte cell component in human adipose tissue (the so-called "stromal vascular fraction" or SVF) can be isolated using collagenase treatment (Rodbell, *Journal of Biol Chem.*, (1967) 242:5744-5750; Rodbell, *et al.*, *Meth Enzymol*, (1974) 31:103-14; the contents of which are incorporated herein by reference). The isolated human preadipocytes can then be driven to differentiate into adipocytes by a variety of chemical treatments. For example, Hauner's

15 laboratory (Hauner, *et al.*, *Journal Clin Invest.*, (1989) 34:1663-1670; the contents of which are incorporated herein by reference) has shown that human preadipocytes can be induced to differentiate in serum-free medium containing 0.2 nM triiodothyronine, 0.5 μ M insulin and 0.1 μ M glucocorticoid (cortisol, dexamethasone or aldosterone). Under these conditions, differentiation of 5-70% of the preadipocytes was achieved. The

20 percentage of differentiated cells was related to the age of the subject from which the cells were obtained. These investigators claim they can achieve anywhere from 5-70% complete differentiation within 20 days as determined by a variety of biochemical markers. Similarly, O'Rahilly's laboratory (Digby, *et al.*, *Diabetes*, (1998) 5:138-141; the contents of which are incorporated by reference) have shown that when the above

25 serum-free medium is supplemented with a TZD such as BRL 49653, differentiation of

20% of omental preadipocytes and 50-80% of subcutaneous and perirenal preadipocytes is achieved.

A method of differentiating human preadipocytes to adipocytes at higher frequency in a shorter period of time and with greater consistency would aid in the study 5 of obesity and diabetes. The present invention provides methods and compositions for the consistent differentiation of 90-95% of human preadipocytes. Several methodologies are provided for different and selective applications.

10

SUMMARY OF THE INVENTION

The present invention provides methods and compositions for the consistent and quantitative differentiation of human preadipocytes isolated from adipose tissue into 15 adipocytes bearing biochemical, genetic, and physiological characteristics similar to that observed in isolated primary adipocytes. The methods of the invention comprise incubating isolated human preadipocytes, plated at least about 25,000 cells/cm², in a medium containing, glucose, a cyclic AMP inducer such as isobutylmethylxanthine or forskolin, a glucocorticoid or glucocorticoid analogue, insulin or an insulin analogue and 20 a PPAR γ agonist or a RXR agonist. The compositions of the invention include media for the differentiation of human preadipocytes, human adipocytes differentiated by the methods of the invention and transfected adipocytes.

The present invention also provides methods for determining the ability of a compound to affect the differentiation of human preadipocytes to adipocytes, for 25 determining the ability of a compound to act as a PPAR γ antagonist, glucocorticoid, glucocorticoid analogue or an insulin analogue, for transfecting cultured human adipocytes, and as a means to identify novel polypeptides secreted from human adipocytes into the conditioned medium. The methods and compositions have use in the drug discovery of compounds having relevance to the disease states of diabetes, obesity, 30 and cardiovascular disease and in the studies of these diseases.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows normal human preadipocytes isolated from subcutaneous adipose tissue (Panel A) and human adipocytes differentiated from preadipocytes using the methods described herein (Panel B).

5 Figure 2 is a graphical representation of the optical density representing staining with Oil Red O of adipocytes differentiated by the methods of the invention in comparison to the Oil Red O staining of preadipocytes.

Figure 3 is a graphical representation of the dose response relationship of BRL49653 in differentiating human preadipocytes.

10 Figure 4 is a graphical representation of the differentiation of human preadipocytes in response to increasing dexamethasone concentrations.

Figure 5 is a graphical representation of the inhibition of differentiation of human preadipocytes by novel compounds.

15 Figure 6 is a graphical representation of the lipolytic response to isoproterenol of human adipocytes differentiated from preadipocytes isolated from five individuals.

Figure 7 is a graphical representation of the β -galactosidase expression at 4, 7 and 14 days post-transfection for human differentiated adipocytes transfected with various amounts of pCMV- β gal in the presence of Effectene.

20 Figure 8 is an autoradiograph of total human preadipocyte and differentiated adipocyte secreted proteins separated by isoelectric focusing and two-dimensional gel electrophoresis.

DETAILED DESCRIPTION OF THE INVENTION

25 The present invention provides methods and compositions for the consistent and quantitative differentiation of human preadipocytes isolated from adipose tissue into adipocytes bearing biochemical, genetic, and physiological characteristics similar to that observed in isolated primary adipocytes. The prior art methods and compositions produce inconsistent differentiation frequencies of 5-80%. See Hauner *et al.* and Digby *et al.*, *supra*. In contrast, the methods of the invention reproducibly achieve 90-95%

differentiation of cultured human preadipocytes into adipocytes and shorten the culture time from 21 to 12 days.

The compositions of the invention relate to media for the differentiation of human preadipocytes into adipocytes. The compositions of the invention can be used according 5 to the methods of the invention to reliably provide a high differentiation frequency of cultured human preadipocytes. Thus, in one aspect, the invention provides a medium for differentiating human preadipocytes into adipocytes comprising: a defined cell culture medium similar to that described (Ham, *Exp Cell Res.*, (1963) 29: 515; Morton, *In Vitro*, (1970) 6:89-108; Dulbecco, *et al.*, *Virology* (1959) 8:396; Smith, *et al.*, *Virology*, (1960) 10 12:185; the contents of which are incorporated herein by reference) having or supplemented with 1.0-4.5 g/liter glucose; a cyclic AMP inducer; 100 nM to 1 μ M insulin or an equivalent amount of an insulin analogue; 16 nM to 1 μ M of a glucocorticoid; and a concentration of a PPAR γ agonist or RXR agonist effective to stimulate differentiation of human preadipocytes.

15 By "preadipocyte" is meant cells that could be isolated from a stromal vascular fraction prepared from adipose tissue, and that have the potential to differentiate into adipocytes. However, the preadipocytes used in the methods of the invention may be isolated by any means known to those skilled in the art. Preferably, the preadipocytes are isolated from a stromal vascular fraction prepared from adipose tissue.

20 By a "defined cell culture medium" is meant a serum free, chemically defined cell growth medium. Preferably the medium is Dulbecco's Modified Eagle Medium /Ham's F-10 Nutrient Broth (1:1 v/v) or Earl's medium (Earle, 1943 *JNCI* 4:165-169; the contents of which are incorporated herein by reference). However, a variety of media, known to those skilled in the art, are useful in the methods of the invention. Additional 25 compounds may be included or added to the medium. For example, antibiotics, such as penicillin, streptomycin and fungizone are useful additives to the media of the invention. Also, the addition to the media of about 0.5-100 μ M biotin, preferably about 10-60 μ M biotin, more preferably about 30-35 μ M biotin, most preferably about 33 μ M biotin; and about 0.5-100 μ M pantothenate, preferably 5-50 μ M pantothenate, more preferably 15-25 30 μ M pantothenate, most preferably about 17 μ M pantothenate, may be useful in promoting cell growth.

The pH of the medium must be maintained at a pH of about 7.0 to 7.6 during use, either through the inclusion of a biological buffer or by adjusting the CO₂ content in the atmosphere of the incubator. A "biological buffer" is a mixture of a weak acid and its conjugate base that tends to resist changes in pH when small amounts of acid or base are added. Typical biological buffers include, but are not limited to, phosphate and carbonate buffering systems. Preferably, the medium will be maintained at a pH of about 7.2-7.5, more preferably 7.3 to 7.5, most preferably at a pH of about 7.4. Preferably the medium is buffered by about 15 mM NaHCO₃ and about 15 mM HEPES, at a pH of about 7.3-7.5, preferably at a pH of about 7.4.

10 Fetal bovine serum (FBS) may be added to the defined cell culture medium at a concentration of about 0 to 15%, preferably about 0-10%, most preferably about 3-10%. A concentration of at least about 3% FBS is necessary to ensure that the cells attach firmly to the tissue culture container. However, FBS is not critical for cell differentiation. For example, cells from the stromal vascular fraction may be induced to differentiate into 15 adipocytes in the absence of FBS. In such cases, when changing the media, the cells would have to be recovered by filtration, centrifugation or similar means, since they would not be attached to the culture ware.

By "cyclic AMP inducer" is meant any compound that, in an effective concentration, increases the intracellular concentration of cAMP in a preadipocyte or 20 adipocyte by at least 2%, preferably by at least 5%, more preferably by at least 10%, most preferably by at least 20%. Methods for measuring intracellular cAMP levels are known to those skilled in the art. Preferred cyclic AMP inducers include isobutylmethylxanthine and forskolin. Preferably, the cyclic AMP inducer is 0.2 to 5 mM isobutylmethylxanthine, more preferably, 0.5 to 0.5 mM isobutylmethylxanthine.

25 By "insulin" is meant any naturally occurring or recombinant mammalian insulin. Preferably the insulin is naturally occurring or recombinant human insulin. By "equivalent amount of an insulin analogue" is meant an amount of a compound that stimulates the differentiation of human stromal vascular cells to adipocytes, using the methods and media of the invention, to the same degree as does 100 nM to 1 μ M human insulin. Such insulin analogues may or may not be structurally related to insulin and may 30 be naturally occurring synthetic or recombinant. The percentage of preadipocytes that

differentiate into adipocytes may be quantitatively determined by a variety of methods known to those skilled in the art. A preferred method is by Oil Red O staining (Green, *supra*).

By "glucocorticoid" is meant any steroid or steroid-like compounds and functional derivatives thereof, which is capable of inducing the differentiation of preadipocytes into adipocytes, using the media and methods of the invention. Preferably, the glucocorticoid is dexamethasone, hydrocortisone or cortisol. A physiological concentration of glucocorticoid is used. Preferably the concentration of glucocorticoid is about 16 nM to 1 μ M, more preferably about 100 nM to 1 μ M, most preferably the concentration of glucocorticoid is about 1 μ M.

By "PPAR γ agonist" is meant a compound capable of activating the peroxisome proliferator-activated receptor gamma (PPAR γ) by at least 10% over background. PPAR γ activation may be determined by the method described by Lehmann *et al. supra*. Preferably the PPAR γ agonist is a thiazolidinedione or a derivative or analogue thereof. More preferably the PPAR γ agonist is BRL 49653, pioglitazone, troglitazone, darglitazone, ciglitazone, AD5075, AD5080, AD4742 or AD4743. Most preferably the PPAR γ agonist is BRL 49653 or troglitazone and the concentration of BRL 49653 or troglitazone is about 0.5-1.0 μ M. More preferably the concentration of BRL 49653 or troglitazone is about 0.8-1.0 μ M, most preferably the concentration is about 1.0 μ M.

By "RXR agonist" is meant a compound capable of activating a retinoic acid X receptor (RXR) by at least 10% over background. RXR activation may be determined by the method described by Heyman *et al.* (1992 *Cell* 68:397-406; the contents of which are incorporated by reference). Preferably, the RXR agonist is LG1069 or *cis*-retinoic acid. Preferably the concentration of LG1069 or *cis*-retinoic acid is about 100 nM to 10 μ M, most preferably the concentration is about 1 μ M.

By "effective to stimulate the differentiation of human preadipocytes" is meant having at least about the same effect on the ability to stimulate differentiation of human preadipocytes to adipocytes using the methods of the invention, as does 0.5-1.0 μ M BRL 49653. The percentage of preadipocytes that differentiate into adipocytes may be quantitatively determined by a variety of methods known to those skilled in the art. A preferred method is by Oil Red O staining.

The methods of the invention utilize the above media to achieve at least 90%, typically 90-95%, differentiation of cultured human preadipocytes into adipocytes. Thus, it is a further object of the invention to provide methods for differentiating human preadipocytes into adipocytes, comprising:

- 5 a) plating isolated human preadipocytes at a density of about 25,000 to 30,000 cells/cm² in a preadipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose;
- b) incubating said cells at about 37°C for about 4-48 hours until said cells are about 95-100% confluent;
- 10 c) replacing said preadipocyte medium with a differentiation medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose, 0.2 to 0.5 mM isobutylmethylxanthine; 100 nM to 1 μM insulin, or an equivalent amount of an insulin analogue; 16 nM to 1 μM of a glucocorticoid; and a concentration of a PPAR γ agonist or RXR agonist effective to stimulate differentiation of human preadipocytes;
- 15 d) incubating said cells at about 37°C for about 2-4 days;
- e) replacing said differentiation medium with an adipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; 100 nM to 1 μM insulin, or an equivalent amount of an insulin analogue; 16 nM to 1 μM of a glucocorticoid; and
- 20 f) incubating said cells at about 37°C for about 1-2 weeks and refeeding said cells with said adipocyte medium at least every 3-4 days; wherein said preadipocyte medium, said differentiation medium and said adipocyte medium are maintained at a pH of about 7.0 to 7.6 when in contact with said cells.

25 Human adipose tissue from a variety of sources may be processed to produce preadipocytes for the generation of adipocytes. The adipose tissue may be from subcutaneous or perirenal sites. Preferably the adipose tissue is subcutaneous. Liposuction surgery or penniculectomy may provide subcutaneous adipose tissue.

 Preadipocytes may be isolated from adipose tissue by a variety of methods known to those in the art. Preferably the preadipocytes are isolated from the stromal vascular fraction by the method of Rodbell (1974), *supra*.

When initially plating preadipocytes in preadipocyte medium (step a), the cells must be plated at a density of 25,000-40,000 cells/cm². Preferably the cell density is 25,000-30,000 cells/cm². Lower density plating of preadipocytes results in an overall lower differentiation percentage. When plated at a density of 25,000 cells/cm² the 5 preadipocytes are usually confluent after overnight incubation. If cells are not fully confluent at this point, they may be incubated for up to another 24 hours prior to refeeding with differentiation medium. Longer incubations will result in a lower differentiation percentage.

Once the cells have been exposed to differentiation media (step c), they are 10 susceptible to detaching from the plate if the media is either completely removed or quickly added. When the differentiation or adipocyte medium is changed, care should be taken to leave a layer of medium over the cell surface (approximately 30-50 µl/well for a 96-well plate).

Formation of oil droplets, a characteristic of adipocytes, will occur approximately 15 four days after differentiation medium is added. However, there will be some variation related to inter-patient variability and the site from which the preadipocytes were isolated. In general, at least 90%, typically 90-95% of cells, will differentiate under the above conditions.

A further object of the invention is to provide methods for the identification and 20 study of compounds that enhance preadipocyte differentiation to adipocytes. It has been demonstrated that many compounds that enhance the differentiation of preadipocytes to adipocytes play a role in the treatment of diabetes mellitus. For example, compounds such as insulin, glucocorticoids, and peroxisome proliferator activated receptor gamma (PPAR γ) activators effect glucose clearance and mediate the differentiation of 25 preadipocytes to adipocytes. Insulin and RezulinTM (a PPAR γ activator) are currently used to treat diabetes in the U.S. Compounds that affect human adipocyte differentiation or lipogenesis may be useful in the treatment of diabetes and obesity. Such compounds include PPAR γ agonists, RXR agonists and insulin analogues.

Accordingly, a method is provided for determining the ability of a compound to 30 affect the differentiation of preadipocytes to adipocytes, comprising:

a) plating isolated human preadipocyte cells at a density of about 25,000 to 40,000 cells/cm² in a preadipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose;

5 b) incubating said cells at about 37°C for about 4-48 hours until said cells are about 95-100% confluent;

10 c) replacing said preadipocyte medium with a differentiation medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; a cyclic AMP inducer; 100 nM to 1 µM insulin, or an equivalent amount of an insulin analogue; 16 nM to 1 µM of a glucocorticoid; and said compound in an appropriate vehicle or vehicle alone;

15 d) incubating said cells at about 37°C for about 2-4 days;

e) replacing said differentiation medium with an adipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; 100 nM to 1 µM insulin, or an equivalent amount of an insulin analogue; and 16 nM to 1 µM of a glucocorticoid;

20 f) incubating said cells at about 37°C for about 1-2 weeks and refeeding said cells with said adipocyte medium at least every 3-4 days; and

g) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with said differentiation medium containing said compound;

25 h) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with said differentiation medium containing said vehicle alone; and

i) comparing the number or percentage of differentiated cells from steps (g) and (h);

wherein said preadipocyte medium, said differentiation medium and said adipocyte medium are maintained at a pH of about 7.0 to 7.6 when in contact with said cells.

30 Any compound may be tested for its ability to affect the differentiation of preadipocytes to adipocytes. Compounds of particular interest include agonists of PPAR γ and/or RXR receptors, such as TZDs. Appropriate vehicles compatible with the

compound to be tested are known to those skilled in the art and may be found in a current edition of Remington 's Pharmaceutical Sciences, the contents of which are incorporated herein by reference. Examples of appropriate vehicles include, but are not limited to, DMSO, DMF or ethanol solutions and a variety of aqueous buffers.

5 A variety of methods known to those skilled in the art may be used to determine the percentage of differentiated cells. Examples of such methods include those that assess biochemical or morphological characteristics, such as lipid deposits and adipocyte-specific proteins or mRNAs. In a preferred method, the cells are fixed in formalin and stained with Oil Red O dye.

10 In another embodiment, the invention provides a method for determining the ability of a compound to act as a PPAR γ antagonist. Thus, the invention provides a method for determining the ability of a compound to act as a PPAR γ antagonist, comprising:

15 a) plating isolated human preadipocyte cells at a density of about 25,000 to 40,000 cells/cm² in a preadipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose;

20 b) incubating said cells at about 37°C for about 4-24 hours until said cells are about 95-100% confluent;

25 c) replacing said preadipocyte medium with a differentiation medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; a cyclic AMP inducer; 16 nM to 1 μ M of a glucocorticoid; 100 nM to 1 μ M insulin, or an equivalent amount of an insulin analogue; and a concentration of a PPAR γ agonist or RXR agonist effective to stimulate differentiation of a human preadipocytes; and said compound in an appropriate vehicle or vehicle alone;

30 d) incubating said cells at about 37°C for about 2-4 days;

 e) replacing said differentiation medium with an adipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; 16 nM to 1 μ M of a glucocorticoid; 100 nM to 1 μ M insulin, or an equivalent amount of an insulin analogue; and said compound in an appropriate vehicle or vehicle alone;

- f) incubating said cells at about 37°C for about 1-2 weeks and refeeding said cells at least every 3-4 days with said adipocyte medium; and
- g) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with medium containing said compound;
- 5 h) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with medium containing said vehicle alone; and
- i) comparing the number or percentage of differentiated cells from steps (g) and (h);

10 wherein said preadipocyte medium, said differentiation medium and said adipocyte medium are maintained at a pH of about 7.0 to 7.6 when in contact with said cells.

A variety of PPAR γ agonists may be used. Preferentially, the PPAR γ agonist is a TZD. Preferably the PPAR γ agonist is BRL 49653 at a concentration of about 1-500 nM, preferably about 10-100 nM, most preferably about 50 nM.

15 In yet another embodiment the invention provides a method for determining the ability of a compound to act as a glucocorticoid or glucocorticoid analogue, comprising:

- a) plating isolated human preadipocyte cells at a density of about 25,000 to 40,000 cells/cm² in a preadipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose;
- 20 b) incubating said cells at about 37°C for about 4-24 hours until said cells are about 95-100% confluent;
- c) replacing said preadipocyte medium with a differentiation medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; a cyclic AMP inducer; 100 nM to 1 μ M insulin, or an equivalent amount of an insulin analogue; and a concentration of a PPAR γ agonist or RXR agonist effective to stimulate differentiation of a human preadipocytes; and said compound in an appropriate vehicle or vehicle alone;
- 25 d) incubating said cells at about 37°C for about 2-4 days;
- e) replacing said differentiation medium with an adipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter

glucose; 100 nM to 1 μ M insulin, or an equivalent amount of an insulin analogue; and said compound in an appropriate vehicle or vehicle alone;

- f) incubating said cells at about 37°C for about 1-2 weeks and refeeding said cells at least every 3-4 days with said adipocyte medium; and
- 5 g) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with medium containing said compound;
- h) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with medium containing said vehicle alone; and
- 10 i) comparing the number or percentage of differentiated cells from steps (g) and (h);

wherein said preadipocyte medium, said differentiation medium and said adipocyte medium are maintained at a pH of about 7.0 to 7.6 when in contact with said cells.

15 In still another embodiment the invention provides a method for determining the ability of a compound to act as an insulin analogue, comprising:

- a) plating isolated human preadipocyte cells at a density of about 25,000 to 40,000 cells/cm² in a preadipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose;
- 20 b) incubating said cells at about 37°C for about 4-24 hours until said cells are about 95-100% confluent;
- c) replacing said preadipocyte medium with a differentiation medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; a cyclic AMP inducer; 16 nM to 1 μ M of a glucocorticoid; and a concentration of a PPAR γ agonist or RXR agonist effective to stimulate differentiation of a human preadipocytes; and said compound in an appropriate vehicle or vehicle alone;
- 25 d) incubating said cells at about 37°C for about 2-4 days;
- e) replacing said differentiation medium with an adipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; 16 nM to 1 μ M of a glucocorticoid; and said compound in an appropriate vehicle or vehicle alone;

- f) incubating said cells at about 37°C for about 1-2 weeks and refeeding said cells at least every 3-4 days with said adipocyte medium; and
- g) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with medium containing said compound;
- 5 h) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with medium containing said vehicle alone; and
- i) comparing the number or percentage of differentiated cells from steps (g) and (h);

10 wherein said preadipocyte medium, said differentiation medium and said adipocyte medium are maintained at a pH of about 7.0 to 7.6 when in contact with said cells.

15 A number of studies have suggested that compounds that can induce lipolysis in adipocytes may have utility in treating obesity or cardiovascular disease. The adipocytes differentiated according to the methods of the invention are responsive to lipolytic agents such as norepinephrine and isoproterenol, a β -adrenoreceptor agonist. When stimulated by lipolytic compounds, triglycerides in adipocytes are converted to glycerol and fatty acids. The glycerol is then released from the cells to the medium. Measurement of glycerol in the conditioned medium is an indication of the response of adipocytes to a lipolytic agent. Accordingly, the mature differentiated adipocytes of the invention may be 20 used to identify and study compounds affecting lipolysis. The ability of a compound to stimulate lipolysis in human adipocytes may also be investigated using this system. Upon full differentiation of the adipocytes, compounds can be added to the cell system to determine their ability to stimulate lipolysis via glycerol production. Glycerol concentration may then be determined using standard methods (Barham, *et al.*, *Analyst*, 25 (1972) 97:142; the contents of which are incorporated herein by reference).

30 The ability to introduce exogenous DNA transiently into cultured human adipocytes will enable the investigator to analyze production of proteins in the adipocyte, characterize promoter regions of adipocyte-selective genes, and identify compounds that affect the expression and regulation of both these described systems. In systems used prior to the instant invention, the inability to obtain an enriched (>90%) population of differentiated adipocytes hampered the use of transfecting exogenous DNA for the

purposes of analysis of gene expression. The mixture of preadipocytes and adipocytes in varying proportions precludes the precise analysis of gene regulation because of the existence of two cell types. The availability of a relatively pure population of adipocytes allows for the precise and careful analysis of gene expression via the introduction of 5 exogenous DNA. Thus, in still another embodiment, the invention provides transfected adipocytes differentiated from preadipocytes by the methods of the invention. A variety of transfection protocols using agents known to those skilled in the art, such as calcium phosphate (Wigler, *et al.*, *Cell*, (1977) 11:223-231); lipofectin; (Felgner, *et al.*, *Proc Natl Acad Sci USA*, (1987) 87:7413-7417); or Effectene may be used. Alternatively, viral 10 particles that can infect preadipocytes, for example, adenovirus, may be used to introduce DNA into the stromal cells similarly to the protocols described (Becker, *et al.*, *Meth Cell Biol*, (1994) 43:161-189; Meunier-Durmont, *et al.*, *Eur Jour Biochem*, (1996) 237:660-667; the contents of which are incorporated herein by reference). The cells are then 15 treated so they differentiate into adipocytes as described above in Example I. An addition of an antibiotic selection marker allows enrichment for cells bearing the introduced genetic material. The derived adipocytes bearing the introduced genetic material may then be used to study gene regulation as described above.

The ability of the adipocyte to function as an endocrine organ has been validated, in part, 20 by the discovery of leptin, a protein secreted almost exclusively by adipocytes which regulated energy homeostasis in mammals. Other examples include the ability of adipocytes to secrete vascular endothelial growth factor, the agouti protein, and angiotensinogen. All of these proteins/peptides have marked effects on wound healing and angiogenesis, obesity, and cardiovascular function, respectively. The invention of a 25 facile human adipocyte culture system allows the systematic identification of proteins and peptides secreted by these cells. Thus, in still another embodiment, the invention provides a method for identifying proteins and peptides secreted from cultured human adipocytes, comprising fractionating the conditioned media of adipocytes differentiated from preadipocytes by the methods of the invention. The following examples are offered by way of illustration and not by way of limitation

EXPERIMENTAL

Example 1

Differentiation of Human Preadipocytes into Adipocytes

5

Human preadipocytes were isolated from adipose tissue removed by liposuction surgery according to the procedures previously described by Rodbell and Hauner (Rodbell (1967) and (1974); Hauner, *supra*). Preadipocytes from the stroma-vascular fraction were resuspended in preadipocyte medium (DME-Ham's F-10, 1:1 (v/v), 10% FBS, and penicillin-streptomycin-fungizone) and plated at 25,000 cells/well in each of the wells of a 96 well plate (150 μ l/well). The cells were then placed in a 37°C 5% CO₂ incubator and allowed to settle overnight. The following day, all of the medium was removed and replaced with 150 μ l differentiation medium (Dulbecco's Modified Eagle Medium/Ham's F-10 Nutrient Broth (1:1, vol/vol), 15 mM HEPES buffer, pH 7.4, 33 μ M biotin, 17 μ M pantothenate, 0.2 mM isobutylmethylxanthine, 100 nM insulin, 1 μ M dexamethasone, 1 μ M BRL 49653 (diluted into medium from a 100X DMSO stock solution), 10% (vol/vol) fetal bovine serum, 60 U/l streptomycin, 60 U/l penicillin and 25 μ g/l Fungizone). The cells were maintained on differentiation medium for 3 days. Additional differentiation medium was added as necessary to maintain the proper volume. 120 μ l of the medium was removed, taking care to leave a 30 μ l layer over the cell surface to prevent the maturing adipocytes from lifting off of the plate surface due to the surface tension created by removal of all the fluid. The cells were then fed with 120 μ l adipocyte medium (Dulbecco's Modified Eagle/Ham's nutrient broth F-10 (1:1, v/v), 15 mM HEPES, pH 7.4, 3% fetal bovine serum, 33 μ M biotin, 17 μ M pantothenate, 100 nM insulin, 1 μ M dexamethasone, 60 U/l penicillin, 60 U/l streptomycin and 25 μ g/l Fungizone) and incubated at 37°C. The cells were refed with the adipocyte medium every 3-4 days for 14 days. At each feeding, 100 μ l of old medium was removed and replaced with 100 μ l fresh medium.

30

Oil droplets appeared approximately 4 days after differentiation medium was added. Adipocytes could be maintained for one week to three months by re-feeding with adipocyte medium every three to four days. Figure 1 illustrates the normal and expected morphology observed for preadipocytes and adipocytes stained with oil red O.

5 The following procedure was used to determine the amount of lipid that had accumulated in the adipocytes. 120 μ l/well of medium was removed from each well of the 96-well plates. Care was taken to prevent drying of the wells. 100 μ l/ well fixer solution (7% formaldehyde in PBS) was added and the plate was incubated at room temperature for at least 2 hours. Oil Red O working solution was prepared by adding 4
10 ml distilled water to 6 ml Oil Red O stock solution (1% Oil Red O in isopropanol). The working solution was incubated for 20 minutes at room temperature and then filtered through Nalgene 0.8 μ m filter wear. All of the fixer was removed by aspiration until wells were completely dry.

15 The cells were then incubated with 40 μ l/well Oil Red O working solution at room temperature for 10-15 minutes. Care was taken not to touch the sides of the wells in order to prevent high background due to dye stuck on the wall of the well. The plate was covered during incubation to prevent evaporation. Following this incubation, all of
20 the Oil Red O solution was removed and the cells were washed four times with 200 μ l/well distilled water. The wash water was drawn off from the top by inserting the manifold or pipette tips to the top of the liquid to remove Oil Red O precipitates floating at the surface. All of the remaining wash water was removed.

25 Isopropanol (100 μ l/well) was then added and the plate was incubated at room temperature for 10 minutes. The isopropanol was pipetted up and down several times, to ensure that all of the Oil Red O was in solution. The optical density was measured at 500 nm. A five-fold increase in staining was observed for differentiated adipocytes as compared to preadipocytes (Figure 2). The average reading for stained adipocytes was 0.383 ± 0.020 OD₅₀₀. The average reading for the stained preadipocytes was 0.082 ± 0.014 OD₅₀₀. A uniform differentiation of cells in each plate was observed.

Example 2

Identification of Compounds that Enhance Preadipocyte Differentiation to
Adipocytes

5 To test the ability of a compound to stimulate differentiation of preadipocytes to adipocytes, the procedures of Example 1 were followed with the following modifications. BRL 49653 was omitted from the differentiation medium and replaced with the compound to be tested or with vehicle alone as a negative control. BRL 49653 was used as a positive control. Various concentrations of BRL49653 in DMEM/F-10 medium
10 containing 3% fetal calf serum, 100 nM insulin, 1 μ M dexamethasone, and 0.2 mM isobutylmethylxanthine were incubated with the cells for 3 days and then adipocyte media without BRL49653. After 9 days the cells were washed, fixed and stained with Oil Red O as described herein. The Oil Red O was extracted, quantitated spectrophotometrically and the results plotted as BRL49653 concentration versus optical density (OD). Figure 3
15 illustrates the dose responsive effect of BRL49653 on the ability to differentiate human preadipocytes as measured by Oil Red O staining.

Example 3

Identification of Glucocorticoids and Glucocorticoid Analogues

20 To test the ability of a compound to act as a glucocorticoid and/or glucocorticoid analogue, the procedures of Example 1 were followed with the following modifications. Human preadipocytes were isolated and cultured in DMEM/F-10 medium containing 3% fetal calf serum, 100 nM insulin, 0.2 mM isobutylmethylxanthine with increasing
25 concentrations of dexamethasone under the conditions described herein for 3 days. The media was then replaced with DMEM/F10 (1:1) containing 3% fetal calf serum, 100 nM insulin and increasing concentrations of dexamethasone. The cells were fed with this medium every three days for 12 days. Cells were then washed, fixed and stained with Oil Red O as described above. Figure 4 illustrates the ability of dexamethasone to stimulate
30 differentiation in a dose-dependent manner, as measured by lipid accumulation.

Example 4
Identification of PPAR γ Antagonists

To test the ability of compounds to act as a PPAR γ antagonist, the procedures of
5 Example 1 were followed with the following modifications. The compound to be tested,
or vehicle alone as a negative control, was added to the differentiation medium containing
BRL49653 at 50 nM, which allows for half maximal stimulation of differentiation. In
this case, human preadipocytes were isolated and cultured in DMEM/F-10 medium
containing 3% fetal calf serum, 100 nM insulin, 50 nM BRL49653, 1 μ M
10 dexamethasone, 0.2 mM isobutylmethylxanthine and 1 μ M of a number of novel
compounds for 3 days. Cells were incubated with standard adipocyte medium for an
additional 10 days. Cells were then washed, fixed and stained with Oil Red O as
described.

Figure 5 illustrates the screening of a variety of novel compounds at a single dose
15 to determine the ability to inhibit differentiation. The graph shows the optical density
plotted versus the various compounds examined. The horizontal line at approximately
0.2 OD is the Oil Red O absorbance observed in the presence of 1 μ M BRL49653, which
is indicative of 100% differentiation. A number of compounds appear to inhibit half
maximal differentiation as measured by Oil Red O staining, since 50 nM BRL4953 yields
20 approximately 0.2 OD units (horizontal line).

Example 5

Identification of Compounds that Induce Lipolysis in Differentiated Adipocytes

25 Preadipocytes from 5 individual patients were isolated and differentiated into
adipocytes as described herein. A 96-well plate of adipocytes differentiated by the
method in Example 1 was prepared. After 21 days from plating, the cells were washed in
Krebs-Ringer buffer and treated with increasing concentrations of isoproterenol. The
positive and negative controls (0.5 μ M isoproterenol in KRB and KRB alone,
30 respectively) were added in duplicate. The plates were then incubated at 37°C for four
hours.

When lipolytic agents stimulate adipocytes, triglycerides are converted to glycerol and fatty acids. Lipolytic rate was measured in this example by measuring the glycerol released in the medium. At the end of the incubation time, conditioned medium (100 μ l) from each well was transferred into a new plate. Glycerol standards (1 mM, 0.5 mM, 0.25 mM, 0.1 mM, 0.05 mM, 0.025 mM, 0 mM) were included.

5 Glycerol assay reagent (100 μ l; Sigma glycerol assay kit) was added to each well. The solutions were mixed well and incubated at room temperature for 15 minutes and then the optical density of each well was read at 540 nm. The increase in absorbance at 10 540 nm is directly proportional to glycerol concentration of the sample Figure 6 illustrates the ability of a known lipolytic agent, isoproterenol, to dose-dependently stimulate lipolysis in differentiated adipocytes isolated from five different patients.

Example 6

Introduction of DNA into Adipocytes

15

Adipocytes were differentiated from preadipocytes according to the method described in Example 1. 0.1-2.0 μ g pCMV- β gal was added to 150 μ l of Buffer EC (Qiagen Effectene kit, Catalog number 301425, Qiagen, Valencia CA) and then the DNA was allowed to condense in a microcentrifuge tube. 8 μ l enhancer (Qiagen Effectene kit) 20 was then added to the DNA mixture, vortexed for one second and allowed to incubate at room temperature for 2-5 minutes. This mixture was centrifuged briefly to remove drops at the top of the tube. 10 μ l Effectene reagent was then added, vortexed for 10 seconds, and incubated at room temperature for 5-10 minutes. 120 μ l of the old medium was removed (30 μ l should be left in the well) from the cells. 70 μ l of fresh adipocyte 25 medium was then added. Following a 5-10 minute incubation time, 1 ml of medium was added to the DNA mixture. 25 μ l of this final mixture was added to each well. The cells were then incubated for 5 hours. However, Effectene is not toxic and may be left on the cells for any period of time. The cells were then rinsed cells with 80 μ l adipocyte medium and then assayed at 72 hours post-infection for β -galactosidase activity. Figure 30 7 illustrates the dose-dependence of DNA concentration and the effect of time in culture on the transfection efficiency using Effectene, as measured by β -galactosidase activity.

Example 7

Identification of Novel Proteins from Human Cultured Adipocytes and Preadipocytes

5

The following protocol allows identification of novel proteins from adipocytes prepared according to the methods described in Example 1. Preadipocytes and differentiated adipocytes from the same patient were cultured as described in Example 1 and then incubated in methionine-free adipocyte media for 2 hours. 100 μ Ci 35 [S] methionine was then added to the media and cells were incubated with this mixture for 2 hrs. This media was then replaced with adipocyte media containing a 1 mM non-radioactive methionine chase.

To determine the pattern of secreted proteins, 10 ml of conditioned media was removed from the cells and dialyzed against 4 liters of cold KRB at 4 $^{\circ}$ C for 4 hrs to remove unincorporated 35 [S]methionine from the radiolabeled proteins. Protein concentration and total radioactivity were determined and 50,000 cpm from each sample was mixed 1:1 vol/vol with a 2X dilution buffer (16% NP-40, 2% ampholines, 8 M urea, 7.5 % β -mercaptoethanol, 0.1 % bromophenol blue) and immediately loaded onto 12.5 cm long 3% acrylamide gel tube gels containing 8 M urea, 10% NP-40, 5.5% ampholines. 20 Three to four crystals of urea were added to the samples and the tubes agitated until dissolved.

The tubes were placed in an isoelectric focusing chamber with the bottom chamber containing 0.01M H₃PO₄ and the top chamber containing 0.02 M NaOH. The samples were run at 12,000 V-hours at constant amperage (0.25 mA/tube). When the 25 voltage increased to 500 volts, the power control was changed to constant voltage. After 12-16 hrs, the voltage was increased to 1000 volts for 3 hours to focus the proteins.

The tube gels were extruded from their cylinders and incubated in equilibration buffer (10% glycerol, 5% β -mercaptoethanol, 0.1 M Tris, pH 6.8, 2% sodium dodecyl sulfate) for 20 minutes. The gradient gel was then placed horizontally onto a 7.5 % 30 polyacrylamide gel containing 0.1 M Tris-HCl pH 6.8 and 1% SDS for separation via apparent molecular weight.

The gel was run for 4 hours at 120 volts, removed from the plates and fixed in acetic acid:methanol:water (1:7:2 vol/vol) overnight. The gel was then soaked in a 10% glycerol solution for 20 minutes and dried under vacuum and heat. The dried gel was exposed to x-ray film for 24 hrs to determine the pattern of radiolabeled protein on the 5 gel. Figure 8 illustrates the patterns observed after labeling secreted proteins from both human preadipocytes (2 days) and differentiated adipocytes (14 days) from the same patient.

All publications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. Publications are herein incorporated by 10 reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended 15 claims.

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
JULY 10 1986

THAT WHICH IS CLAIMED:

1. A method for determining the ability of a compound to affect the differentiation of preadipocytes to adipocytes, comprising:

- a) plating isolated human preadipocyte cells at a density of about 25,000 to 40,000 cells/cm² in a preadipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose;
- b) incubating said cells at about 37°C for about 4-48 hours until said cells are about 95-100% confluent;
- c) replacing said preadipocyte medium with a differentiation medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; a cyclic AMP inducer; 100 nM to 1 μM insulin, or an equivalent amount of an insulin analogue; 16 nM to 1 μM of a glucocorticoid; and said compound in an appropriate vehicle or vehicle alone;
- d) incubating said cells at about 37°C for about 2-4 days;
- e) replacing said differentiation medium with an adipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; 100 nM to 1 μM insulin, or an equivalent amount of an insulin analogue; and 16 nM to 1 μM of a glucocorticoid;
- f) incubating said cells at about 37°C for about 1-2 weeks and refeeding said cells with said adipocyte medium at least every 3-4 days; and
- g) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with said differentiation medium containing said compound;
- h) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with said differentiation medium containing said vehicle alone; and
- i) comparing the number or percentage of differentiated cells from steps (g) and (h);

wherein said preadipocyte medium, said differentiation medium and said adipocyte medium are maintained at a pH of about 7.0 to 7.6 when in contact with said cells.

2. A method for determining the ability of a compound to act as a PPAR γ antagonist, comprising:

- a) plating isolated human preadipocyte cells at a density of about 25,000 to 40,000 cells/cm² in a preadipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose;
- b) incubating said cells at about 37°C for about 4-48 hours until said cells are about 95-100% confluent;
- c) replacing said preadipocyte medium with a differentiation medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; a cyclic AMP inducer; 100 nM to 1 μ M insulin, or an equivalent amount of an insulin analogue; 16 nM to 1 μ M of a glucocorticoid; and a concentration of a PPAR γ agonist effective to stimulate half-maximal differentiation of a human preadipocytes; and said compound in an appropriate vehicle or vehicle alone;
- d) incubating said cells at about 37°C for about 2-4 days;
- e) replacing said differentiation medium with an adipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; 100 nM to 1 μ M insulin, or an equivalent amount of an insulin analogue; 16 nM to 1 μ M of a glucocorticoid;
- f) incubating said cells at about 37°C for about one week and refeeding said cells at least once with the supplemented medium from step (e); and
- g) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with medium containing said compound;
- h) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with medium containing said vehicle alone; and
- i) comparing the number or percentage of differentiated cells from steps (g) and (h);

wherein said preadipocyte medium, said differentiation medium and said adipocyte medium are maintained at a pH of about 7.0 to 7.6 when in contact with said cells.

3. A method for determining the ability of a compound to act as an insulin analogue, comprising:

- a) plating isolated human preadipocyte cells at a density of about 25,000 to 40,000 cells/cm² in a preadipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose;
- b) incubating said cells at about 37°C for about 4-24 hours until said cells are about 95-100% confluent;
- c) replacing said preadipocyte medium with a differentiation medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; a cyclic AMP inducer; 16 nM to 1 µM of a glucocorticoid; and a concentration of a PPAR γ agonist or RXR agonist effective to stimulate differentiation of a human preadipocytes; and said compound in an appropriate vehicle or vehicle alone;
- d) incubating said cells at about 37°C for about 2-4 days;
- e) replacing said differentiation medium with an adipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; 16 nM to 1 µM of a glucocorticoid; and said compound in an appropriate vehicle or vehicle alone;
- f) incubating said cells at about 37°C for about 1-2 weeks and refeeding said cells at least every 3-4 days with said adipocyte medium; and
- g) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with medium containing said compound;
- h) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with medium containing said vehicle alone; and
- i) comparing the number or percentage of differentiated cells from steps (g) and (h);

wherein said preadipocyte medium, said differentiation medium and said adipocyte medium are maintained at a pH of about 7.0 to 7.6 when in contact with said cells.

4. A method for determining the ability of a compound to act as a glucocorticoid or glucocorticoid analogue, comprising:

- a) plating isolated human preadipocyte cells at a density of about 25,000 to 40,000 cells/cm² in a preadipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose;
- b) incubating said cells at about 37°C for about 4-24 hours until said cells are about 95-100% confluent;
- c) replacing said preadipocyte medium with a differentiation medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; a cyclic AMP inducer; 100 nM to 1 μM insulin, or an equivalent amount of an insulin analogue; and a concentration of a PPAR γ agonist or RXR agonist effective to stimulate differentiation of a human preadipocytes; and said compound in an appropriate vehicle or vehicle alone;
- d) incubating said cells at about 37°C for about 2-4 days;
- e) replacing said differentiation medium with an adipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; 100 nM to 1 μM insulin, or an equivalent amount of an insulin analogue; and said compound in an appropriate vehicle or vehicle alone;
- f) incubating said cells at about 37°C for about 1-2 weeks and refeeding said cells at least every 3-4 days with said adipocyte medium; and
- g) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with medium containing said compound;
- h) determining the number or percentage of differentiated cells in the cells from step (f) fed at step (c) with medium containing said vehicle alone; and
- i) comparing the number or percentage of differentiated cells from steps (g) and (h);

wherein said preadipocyte medium, said differentiation medium and said adipocyte medium are maintained at a pH of about 7.0 to 7.6 when in contact with said cells.

5. A method for introducing DNA into human adipocytes wherein said adipocytes are prepared using a method for differentiating human preadipocytes into adipocytes, comprising:

- a) plating isolated human preadipocytes at a density of about 25,000 to 30,000 cells/cm² in a preadipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose;
- b) incubating said cells at about 37°C for about 4-48 hours until said cells are about 95-100% confluent;
- c) replacing said preadipocyte medium with a differentiation medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose, 0.2 to 0.5 mM isobutylmethylxanthine; 100 nM to 1 μM insulin, or an equivalent amount of an insulin analogue; 16 nM to 1 μM of a glucocorticoid; and a concentration of a PPAR γ agonist or RXR agonist effective to stimulate differentiation of human preadipocytes;
- d) incubating said cells at about 37°C for about 2-4 days;
- e) replacing said differentiation medium with an adipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; 100 nM to 1 μM insulin, or an equivalent amount of an insulin analogue; 16 nM to 1 μM of a glucocorticoid; and
- f) incubating said cells at about 37°C for about 1-2 weeks and refeeding said cells with said adipocyte medium at least every 3-4 days;

wherein said preadipocyte medium, said differentiation medium and said adipocyte medium are maintained at a pH of about 7.0 to 7.6 when in contact with said cells; and wherein said adipocyte is transiently or stably infected with at least one nucleic acid sequence.

6. A method for identifying polypeptides secreted from cultured human adipocytes

prepared from preadipocytes using a method comprising:

- a) plating isolated human preadipocytes at a density of about 25,000 to 30,000 cells/cm² in a preadipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose;
- b) incubating said cells at about 37°C for about 4-48 hours until said cells are about 95-100% confluent;
- c) replacing said preadipocyte medium with a differentiation medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose, 0.2 to 0.5 mM isobutylmethylxanthine; 100 nM to 1 μM insulin, or an equivalent amount of an insulin analogue; 16 nM to 1 μM of a glucocorticoid; and a concentration of a PPAR γ agonist or RXR agonist effective to stimulate differentiation of human preadipocytes;
- d) incubating said cells at about 37°C for about 2-4 days;
- e) replacing said differentiation medium with an adipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose; 100 nM to 1 μM insulin, or an equivalent amount of an insulin analogue; 16 nM to 1 μM of a glucocorticoid; and
- f) incubating said cells at about 37°C for about 1-2 weeks and refeeding said cells with said adipocyte medium at least every 3-4 days;

wherein said preadipocyte medium, said differentiation medium and said adipocyte medium are maintained at a pH of about 7.0 to 7.6 when in contact with said cells; and wherein said method comprises fractionating the polypeptides which are secreted.

METHODS AND COMPOSITIONS FOR THE DIFFERENTIATION OF
HUMAN PREADIPOCYTES INTO ADIPOCYTES

ABSTRACT OF THE DISCLOSURE

The present invention provides methods and compositions for the consistent and quantitative differentiation of human preadipocytes isolated from adipose tissue into adipocytes bearing biochemical, genetic, and physiological characteristics similar to that observed in isolated primary adipocytes. The methods of the invention comprise incubating isolated human preadipocytes, plated at least about 25,000 cells/cm², in a medium containing, glucose, a cyclic AMP inducer such as isobutylmethylxanthine or forskolin, a glucocorticoid or glucocorticoid analogue, insulin or an insulin analogue and a PPAR γ agonist or a RXR agonist. The compositions of the invention include media for the differentiation of human preadipocytes, human adipocytes differentiated by the methods of the invention and transfected adipocytes.

The present invention also provides methods for determining the ability of a compound to affect the differentiation of human preadipocytes to adipocytes, for determining the ability of a compound to act as a PPAR γ antagonist, a glucocorticoid, a glucocorticoid analogue, or an insulin analogue, for transfecting cultured human adipocytes, and as a means to identify novel polypeptides secreted from human adipocytes into the conditioned medium. The methods and compositions have use in the drug discovery of compounds having relevance to the disease states of diabetes, obesity, and cardiovascular disease and in the studies of these diseases.

Figure 1. Human cultured preadipocytes and human cultured differentiated adipocytes.

A.



B.




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7





Figure 8

2-dimensional gel analysis of adipocyte secreted proteins



DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

Attorney Docket No. 5750-8

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

"METHODS AND COMPOSITIONS FOR THE DIFFERENTIATION OF HUMAN
PREADIPOCYTES INTO ADIPOCYTES",

the specification of which

is attached hereto

OR

was filed on 1/29/1999 as United States Application No. 09/240,029

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

Number	Country	MM/DD/YYYY Filed	<input type="checkbox"/> Yes <input type="checkbox"/> No
			Priority Claimed
Number	Country	MM/DD/YYYY Filed	<input type="checkbox"/> Yes <input type="checkbox"/> No
			Priority Claimed
Number	Country	MM/DD/YYYY Filed	<input type="checkbox"/> Yes <input type="checkbox"/> No
			Priority Claimed

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date (MM/DD/YYYY)
Application Number	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application (37 C.F.R. § 1.63(d)).

Application No.	Filing Date	Status Patented/Pending/Abandoned
Application. No.	Filing Date	Status Patented/Pending/Abandoned
Application No.	Filing Date	Status Patented/Pending/Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 000826

Direct correspondence to the
attention of and telephone calls to:

Elaine Sale
Registration No. 41,286
Tel Raleigh Office (919) 420-2200
Fax Raleigh Office (919) 420-2260

Full name of (first/sole) inventor: Yuan-Di Chang Halvorsen

Inventor's

Signature: Yuan-Di Chang Date: 3/26/99

Residence: Holly Springs, North Carolina

Citizenship: United States of America

Post Office Address: 5128 Salem Ridge Road, Holly Springs, North Carolina 27540

Full name of second inventor: William O. Wilkison

Inventor's

Signature: William O. Wilkison Date: 3/26/99

Residence: Bahama, North Carolina

Citizenship: United States of America

Post Office Address: 9706 Gallop Lane, Bahama, North Carolina 27503

RTA01/2061599v1